Our innovation in CardioMetabolic diseases is evidenced through our long history of excellence in research and landmark clinical trials, culminating in our most recent breakthrough treatments in type 2 diabetes and anticoagulation care. We are also committed to discovering and developing the innovations of the future and are searching for differentiated novel products and new therapeutic concepts.

Our specific partnering interests offer various opportunities for collaboration on therapies that address microvascular and macrovascular consequences of diabetes and the metabolic syndrome. While the majority of our partnering takes place between Discovery and Phase 1, we also consider exceptional opportunities with good portfolio fit in more advanced clinical stages.

Liver diseases
- Non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, portal hypertension

Retinopathies
- Geographic atrophy/dry and wet AMD
- Diabetic Retinopathy/DME and related retinal diseases

Novel obesity treatments achieving weight loss > 10%

Breakthrough treatments for type 2 diabetes, such as pancreas recovery options

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...

Working together for better health

For more information please contact our BD&L team:
Dr. Johannes Zanzinger
johannes.zanzinger@boehringer-ingelheim.com

Dr. Monica Cheng
monica.cheng@boehringer-ingelheim.com

Dr. Manuel Baader
manuel.baader@boehringer-ingelheim.com